CRISPR and the Ethics of Human Embryo Research
What U.S. Government Policy Should Be
News that U.S. scientists led by Oregon Health and Sciences University biologist Shoukrat Mitalipov have used the gene-editing technique known as CRISPR to modify the DNA of human embryos has led to renewed debate over human genetic engineering. Although scientists in China and the United Kingdom have already used gene editing on human embryos, the announcement that the research is now being done in the United States makes a U.S. policy response all the more urgent.
The scientists created 131 embryos that carried a genetic mutation that causes hypertrophic cardiomyopathy—a condition that can lead to sudden and unexpected heart attacks but has few other symptoms—and attempted to correct the mutation in 112 of them (leaving 19 as unmodified controls). By injecting the CRISPR complex together with the sperm cells that carried the mutation, rather than injecting CRISPR into already fertilized embryos, the scientists were able to successfully correct the mutated genes in 72 percent of the embryos. Whether the embryos were successfully or unsuccessfully treated, all were destroyed after the researchers were finished with the study.
Much of the debate over CRISPR has been framed around concerns over the creation of so-called designer babies—children genetically engineered to possess desirable traits that will then be passed on to subsequent generations. Some science writers and journalists have tried to downplay these concerns by noting that the gene editing was done only for “basic research,” rather than as an attempt to create a genetically engineered human. Writing in The New York Times, Pam Belluck argued that even if scientists do modify the genes of human embryos, “fears that embryo modification could allow parents to custom order a baby with Lin-Manuel Miranda’s imagination or Usain Bolt’s speed are closer to science fiction than science.”
Those downplaying concerns also argue that preexisting practices such as the abortion of fetuses diagnosed with Down syndrome or the selective discarding of embryos diagnosed with genetic disease through preimplantation genetic diagnosis (PGD) are exactly the reason gene-editing James Kath and Noam Prywes wrote in Scientific American, “the use of CRISPR, as explored in this study, has no clear advantage over PGD.” In a press release responding to the news, the Center for Genetics and Society, an advocacy group broadly opposed to genetic modification of human embryos, made a similar argument, noting that “preventing the transmission of serious inherited diseases does not require gene editing, since that can be avoided safely and in nearly every case with existing embryo screening techniques, where appropriate.” This is cold comfort, however, for those concerned about the destruction of human life for eugenic purposes, who might well consider gene editing to cure genetic disease in embryos as morally preferable to selectively killing embryos diagnosed with a genetic disease.Read the full article on ForeignAffairs.com